ArticleDermatology research and practice2021
Increased Circulatory Interleukin-17A Levels in Patients with Progressive and Leukotrichial Vitiligo.
Article in Dermatology research and practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 12 citations in OpenAlex.
- Genetically predicted immune cells mediates the association between hepatocellular carcinoma and inflammatory proteins: a Mendelian randomization study.Discover oncology · 2025Article
- Vitiligo: From mechanisms of disease to treatable pathways.Skin health and disease · 2024Review
- Markers of Metabolic Abnormalities in Vitiligo Patients.International journal of molecular sciences · 2024Article
- The role of aryl hydrocarbon receptor in vitiligo: a review.Frontiers in immunology · 2024Review
- Vitiligo, from Pathogenesis to Therapeutic Advances: State of the Art.International journal of molecular sciences · 2023Review
- Vitamin D and Interleukin-17: Are These Serum Biomarkers Useful in Non-Segmental Vitiligo? A Case Control Study from Central India.Indian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVitiligo is a chronic condition characterized by skin depigmentation. Although not life-threatening, it significantly impacts quality of life. The pathophysiology of vitiligo remains poorly understood, and treatment options are limited. Mounting evidence supports the importance of autoreactive T cells and, particularly interleukin-17A- (IL-17A-) secreting Th17 cells, in vitiligo. IL-17A targeting has been proven successful in various inflammatory dermatological conditions, including psoriasis and lupus erythematosus.
objectiveWe evaluated the relationship between serum levels of IL-17A and the clinicopathological characteristics of Vietnamese vitiligo patients.
methodsIn this cross-sectional study, we analyzed data from 52 nonsegmental vitiligo patients and 50 age- and sex-matched healthy individuals. Serum levels of IL-17A were measured using an enzyme-linked immunosorbent assay. We evaluated the correlation between IL-17A levels and clinical characteristics including leukotrichia, disease duration, vitiligo activity, and body surface area involvement.
resultsPatients with progressive vitiligo had significantly higher IL-17A levels than patients with stable vitiligo (
conclusionsHigher serum levels of IL-17A in patients with progressive vitiligo and leukotrichia suggest a potential role of IL-17A in melanocyte destruction in the epidermis and the follicular matrix.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.